NanoViricides Inc
NNVC1.585USD
+0.005+0.33%
Market hours （ET）Quotes delayed by 15 min
25.48MMarket Cap
LossP/E TTM
More Details of NanoViricides Inc Company
NanoViricides, Inc. is a clinical-stage company that is creating special purpose nanomaterials for antiviral therapy. Its nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that it plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. It is focused on advancing NV-387 into Phase II human clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 (API NV-387) is its nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is its other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
Company Info
Ticker SymbolNNVC
Company nameNanoViricides Inc
IPO dateAug 12, 2004
CEODr. Anil Diwan, Ph.D.
Number of employees7
Security typeOrdinary Share
Fiscal year-endAug 12
Address1 Controls Drive
CitySHELTON
Stock exchangeNYSE American Consolidated
CountryUnited States of America
Postal code06484
Phone12039376137
Websitehttps://www.nanoviricides.com/
Ticker SymbolNNVC
IPO dateAug 12, 2004
CEODr. Anil Diwan, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Meeta Vyas
Meeta Vyas
Chief Financial Officer
Chief Financial Officer
7.13K
--
Dr. Anil Diwan, Ph.D.
Dr. Anil Diwan, Ph.D.
President, Chief Executive Officer, Executive Chairman of the Board
President, Chief Executive Officer, Executive Chairman of the Board
--
--
Dr. Makarand (Mak) Jawadekar, Ph.D.
Dr. Makarand (Mak) Jawadekar, Ph.D.
Independent Director
Independent Director
--
--
Mr. Theodore Edward (Todd) Rokita, J.D.
Mr. Theodore Edward (Todd) Rokita, J.D.
Independent Director
Independent Director
--
--
Mr. Brian F. Zucker
Mr. Brian F. Zucker
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Meeta Vyas
Meeta Vyas
Chief Financial Officer
Chief Financial Officer
7.13K
--
Dr. Anil Diwan, Ph.D.
Dr. Anil Diwan, Ph.D.
President, Chief Executive Officer, Executive Chairman of the Board
President, Chief Executive Officer, Executive Chairman of the Board
--
--
Dr. Makarand (Mak) Jawadekar, Ph.D.
Dr. Makarand (Mak) Jawadekar, Ph.D.
Independent Director
Independent Director
--
--
Mr. Theodore Edward (Todd) Rokita, J.D.
Mr. Theodore Edward (Todd) Rokita, J.D.
Independent Director
Independent Director
--
--
Mr. Brian F. Zucker
Mr. Brian F. Zucker
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 16
Updated: Wed, Jul 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
3.18%
Theracour Pharma, Inc.
2.93%
BlackRock Institutional Trust Company, N.A.
0.99%
Geode Capital Management, L.L.C.
0.96%
Renaissance Technologies LLC
0.66%
Other
91.29%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
3.18%
Theracour Pharma, Inc.
2.93%
BlackRock Institutional Trust Company, N.A.
0.99%
Geode Capital Management, L.L.C.
0.96%
Renaissance Technologies LLC
0.66%
Other
91.29%
Shareholder Types
Shareholders
Proportion
Investment Advisor
4.91%
Corporation
2.93%
Investment Advisor/Hedge Fund
1.70%
Hedge Fund
0.69%
Individual Investor
0.60%
Venture Capital
0.32%
Research Firm
0.23%
Bank and Trust
0.03%
Other
88.60%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
61
1.83M
11.40%
-362.26K
2025Q1
63
2.05M
12.78%
-124.35K
2024Q4
61
2.03M
12.98%
-23.52K
2024Q3
60
1.91M
13.93%
-126.25K
2024Q2
62
1.91M
16.17%
+50.13K
2024Q1
62
1.74M
14.78%
-267.11K
2023Q4
64
1.76M
14.98%
-214.22K
2023Q3
67
1.72M
14.71%
-264.52K
2023Q2
63
1.75M
15.01%
-221.57K
2023Q1
69
1.77M
15.19%
-341.23K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
510.42K
3.18%
--
--
Mar 31, 2025
Theracour Pharma, Inc.
470.96K
2.93%
--
--
Oct 09, 2024
BlackRock Institutional Trust Company, N.A.
158.75K
0.99%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
154.59K
0.96%
+11.28K
+7.87%
Mar 31, 2025
Renaissance Technologies LLC
105.80K
0.66%
-39.90K
-27.39%
Mar 31, 2025
XTX Markets LLC
51.25K
0.32%
+51.25K
--
Mar 31, 2025
Bridgeway Capital Management, LLC
44.04K
0.27%
--
--
Mar 31, 2025
State Street Global Advisors (US)
41.91K
0.26%
--
--
Mar 31, 2025
City National Rochdale, LLC
30.54K
0.19%
--
--
Mar 31, 2025
Jawadakar (Makarand)
30.50K
0.19%
--
--
Oct 09, 2024
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
